AUS
NZ
UK
CA
USA
IND
Highlights
- Pro Medicus Limited offers essential radiology IT solutions, supporting global healthcare systems.
- The healthcare sector shows resilience and steady growth potential, especially in the IT and data solutions space.
- PME’s share price trades above its historical average, reflecting its revenue growth and unique market position.
Founded in 1983, Pro Medicus Limited (ASX:PME) specializes in radiology IT software, serving hospitals, imaging centers, and healthcare providers worldwide. The company’s innovative suite of products focuses on Radiology Information Systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualizations, supporting a range of essential tasks from patient scheduling to fast medical image analysis. One standout product in their portfolio is the Visage imaging software, which allows radiologists to remotely view large X-ray files on mobile devices. This feature can accelerate diagnostic decisions and ideally enhances patient care.
Strength of the Healthcare Sector
The healthcare industry has demonstrated resilience and steady growth, even through challenging economic conditions. The S&P/ASX200 Healthcare Index (ASX:XHJ) shows consistent performance, with a 3.34% return per year over the past five years, slightly behind the average of all ASX sectors. Healthcare is largely considered essential, with demand remaining strong irrespective of economic cycles. Unlike other industries influenced by commodity prices or seasonality, healthcare spending tends to remain consistent, underlining its “sticky revenue” model. Notably, healthcare outperformed other sectors during the global financial crisis, indicating its relative stability.
Future Growth Potential for IT-Driven Healthcare
In the United States, which represents more than 40% of global healthcare expenditure, annual healthcare profits are expected to grow by around 7% from 2022 to 2027. This trend points to robust growth potential within healthcare, especially for sectors focused on IT and data solutions. Notably, companies engaged in ‘software-as-a-service’ (SaaS) for healthcare are projected to experience growth rates exceeding 15% annually from 2024 to 2030. Pro Medicus, with its focus on radiology IT solutions, is strategically positioned to benefit from this upward trend as healthcare providers increasingly adopt digital tools for improved patient care.
Sustainable and Ethical Investment Appeal
As interest in ethical and sustainable investments rises, Pro Medicus Limited stands out as a healthcare-focused company contributing to essential public services. A recent survey revealed that a significant number of investors are looking to allocate more to sustainable investments in 2024. Sectors like healthcare, which provide critical services, are likely to draw heightened interest from investors focusing on ethical investment principles.
Evaluating PME’s Valuation
When assessing Pro Medicus Limited’s share price, one method is to compare its price-to-sales ratio over time. Currently, PME has a price-sales ratio of 119.90x, above its five-year average of 82.69x. This indicates that its shares trade at a premium compared to historical levels, which may reflect increased investor confidence in the company’s revenue growth over the past three years. Pro Medicus’s focus on innovative and essential healthcare solutions makes it an intriguing option within the resilient and growing healthcare sector.
